Ibandronate Sodium Hydrate/Colecalciferol

伊班膦酸钠/胆骨化醇

Report date: 2022/01/14 13:23:58

Base Information

Drug NameIbandronate Sodium Hydrate/Colecalciferol
Drug Alias Name胆骨化醇/伊班膦酸钠ibandronic acid + colecalciferolCholecalciferol/Ibandronate sodiumibandronate + colecalciferolibandronic acid + vitamin D3 +[8] 
ClassificationSmall molecules
Mechanisms of ActionFarnesyl diphosphate synthase inhibitorsBone resorption factor inhibitorsVitamin D receptor agonists
TargetsVitamin D receptorBone resorption factorFarnesyl diphosphate synthase
Therapy Area/IndicationsOsteoporosis
Global Approved IndicationsOsteoporosis
Approved Indications in ChinaN/A
Original Approved Country/TerritorySouth Korea
Original Approved Date2013/09/01
Country/TerritorySouth Korea
CombinationsYes ColecalciferolIbandronate Sodium Hydrate
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesAlvogen
China Registration ClassN/A

Develop Information

Active CompaniesAlvogen
Inactive CompaniesN/A
Active IndicationsOsteoporosis
Inactive IndicationsN/A

Other Information

ATC CodeM05BB03
Related LinksN/A